StockNews.com initiated coverage on shares of OncoSec Professional medical (NASDAQ:ONCS – Get Score) in a report released on Monday. The brokerage set a “sell” score on the biotechnology company’s inventory.
Separately, BTIG Investigate minimized their concentrate on cost on OncoSec Clinical from $10.00 to $5.00 and established a “buy” rating on the inventory in a report on Wednesday, March 16th.
ONCS inventory opened at $1.06 on Monday. OncoSec Healthcare has a 1-yr small of $.75 and a 1-calendar year superior of $5.55. The organization has a marketplace cap of $41.71 million, a P/E ratio of -1.02 and a beta of 1.99. The business’s 50 working day relocating ordinary is $1.01 and its 200-day transferring typical is $1.27.
OncoSec Medical (NASDAQ:ONCS – Get Rating) very last released its quarterly earnings data on Tuesday, March 15th. The biotechnology corporation documented ($.25) earnings for every share for the quarter, lacking the consensus estimate of ($.11) by ($.14). On typical, study analysts hope that OncoSec Medical will post -.59 earnings per share for the recent fiscal yr.
Large buyers have not too long ago purchased and bought shares of the enterprise. Point out Avenue Corp acquired a new position in OncoSec Professional medical for the duration of the 2nd quarter truly worth $56,000. HighTower Advisors LLC obtained a new situation in OncoSec Medical all through the 3rd quarter really worth $45,000. Goldman Sachs Group Inc. acquired a new position in shares of OncoSec Medical in the 3rd quarter valued at $53,000. Susquehanna Worldwide Group LLP lifted its stake in shares of OncoSec Professional medical by 62.7% in the 4th quarter. Susquehanna Worldwide Group LLP now owns 44,075 shares of the biotechnology company’s inventory valued at $42,000 soon after acquiring an more 16,990 shares in the course of the interval. Eventually, Tocqueville Asset Management L.P. lifted its stake in shares of OncoSec Clinical by 86.8% in the 3rd quarter. Tocqueville Asset Administration L.P. now owns 49,500 shares of the biotechnology company’s stock valued at $105,000 immediately after acquiring an further 23,000 shares during the time period. 16.39% of the stock is at the moment owned by hedge resources and other institutional investors.
OncoSec Health-related Business Profile (Get Ranking)
OncoSec Professional medical, Inc is a biotechnology firm targeted on building, developing and commercializing therapies and proprietary health-related methods to encourage and to guideline an anti-tumor immune response for the treatment method of most cancers. Its guide product prospect, ImmunoPulse IL-12, uses an electroporation product, with the purpose of reversing the immunosuppressive microenvironment in the taken care of tumor.
Highlighted Articles
Want Far more Excellent Investing Ideas?
Get News & Ratings for OncoSec Professional medical Day-to-day – Enter your e mail address down below to get a concise day-to-day summary of the hottest information and analysts’ scores for OncoSec Health-related and associated businesses with MarketBeat.com’s Free of charge every day electronic mail e-newsletter.
